Napa Wealth Management Takes $267,000 Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Napa Wealth Management bought a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 449 shares of the biotechnology company’s stock, valued at approximately $267,000.

Several other large investors have also recently made changes to their positions in AXON. Wealth Enhancement Advisory Services LLC increased its position in shares of Axon Enterprise by 1.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,607 shares of the biotechnology company’s stock valued at $7,493,000 after purchasing an additional 185 shares during the last quarter. Czech National Bank raised its stake in Axon Enterprise by 7.4% in the 4th quarter. Czech National Bank now owns 15,707 shares of the biotechnology company’s stock valued at $9,335,000 after acquiring an additional 1,082 shares during the period. Brookstone Capital Management raised its stake in Axon Enterprise by 27.0% in the 4th quarter. Brookstone Capital Management now owns 974 shares of the biotechnology company’s stock valued at $579,000 after acquiring an additional 207 shares during the period. MRA Advisory Group raised its stake in Axon Enterprise by 64.4% in the 4th quarter. MRA Advisory Group now owns 3,205 shares of the biotechnology company’s stock valued at $1,905,000 after acquiring an additional 1,255 shares during the period. Finally, 180 Wealth Advisors LLC bought a new stake in Axon Enterprise in the 4th quarter valued at about $220,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares of the company’s stock, valued at approximately $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeri Williams sold 307 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the transaction, the director now directly owns 1,627 shares of the company’s stock, valued at $899,275.44. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,964 shares of company stock valued at $12,189,275. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Stock Up 4.6%

AXON stock opened at $724.77 on Wednesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $56.42 billion, a PE ratio of 187.28, a PEG ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $732.17. The stock has a 50-day simple moving average of $572.18 and a two-hundred day simple moving average of $588.52.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.15 EPS. On average, equities analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

AXON has been the topic of a number of research reports. Craig Hallum cut Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Barclays boosted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Finally, Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $640.91.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.